Quantcast

AstraZeneca reorganization to cut 1,600 jobs in U.S., U.K.

Published March 18, 2013 9:24 am

This is an archived article that was published on sltrib.com in 2013, and information in the article may be outdated. It is provided only for personal research purposes and may not be reprinted.

WILMINGTON, Del. • British drugmaker AstraZeneca PLC is eliminating 1,600 jobs, mostly in the U.S. and United Kingdom, under a global restructuring meant to reduce costs and make research programs more productive.

The cuts amount to nearly 3 percent of AstraZeneca's 57,200 workers around the world. The world's fifth-largest drugmaker by revenue also will move its global headquarters from London to Cambridge, England, by 2016.

In the U.S., AstraZeneca will scale back its site in Wilmington, Del., eliminating about 650 jobs and shifting 550 more to other company locations.

About 300 of those jobs will be moved to Gaithersburg, Md., home to the company's MedImmune subsidiary and the main location for AstraZeneca's research on biologic drugs. It will take over Wilmington's role heading global medicine development for both pills and injectable biologic drugs.

USER COMMENTS
Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
comments powered by Disqus